Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function

被引：2

作者：

Begic, Edin ^{[1
,2
]}

Causevic, Mirsada ^{[2
]}

机构：

[1] Gen Hosp Prim Dr Abdulah Nakas, Dept Cardiol, Sarajevo, Bosnia & Herceg

[2] Sarajevo Sch Sci & Technol, Sarajevo Med Sch, Dept Pharmacol, Sarajevo, Bosnia & Herceg

来源：

HEART LUNG AND CIRCULATION | 2021年 / 30卷 / 11期

关键词：

Alzheimer's disease; Atherosclerosis; Glucagon-like peptide 1; Neurodegenerative diseases; Therapeutics; CARDIOVASCULAR-DISEASE; MOLECULAR-MECHANISMS; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; MEMORY IMPAIRMENT; MOUSE MODEL; BLOOD-FLOW; LIRAGLUTIDE; ATHEROSCLEROSIS; RISK;

D O I：

10.1016/j.hlc.2021.07.024

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prevention of cardiovascular events and regression of atherosclerotic changes are the primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by endothelial dysfunction, which disrupts vascular haemostasis. Glucagon-like peptide 1 (GLP-1) receptor agonists have been initially used as glucose lowering agents, but over time have been used for other indications due to their cardiorenal benefit, as well as their benefit in the regression of atherosclerosis process. The aim of this paper is to present the benefits of GLP-1 receptor agonists in the prevention of atherosclerotic changes, in the preservation of brain vascular function, and to show the possible role in the treatment of neurodegenerative diseases.

引用

页码：1675 / 1680

页数：6

共 63 条

[1] Coagulation and fibrinolysis in diabetes [J].

Alzahrani, S. H. ;

Ajjan, R. A. .

DIABETES & VASCULAR DISEASE RESEARCH, 2010, 7 (04) :260-273

[2] Coronary Artery Disease and Diabetes Mellitus [J].

Aronson, Doron ;

Edelman, Elazer R. .

CARDIOLOGY CLINICS, 2014, 32 (03) :439-+

[3]

Babic N, 2011, MED GLAS, V8, P134

[4] An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers [J].

Bomfim, Theresa R. ;

Forny-Germano, Leticia ;

Sathler, Luciana B. ;

Brito-Moreira, Jordano ;

Houzel, Jean-Christophe ;

Decker, Helena ;

Silverman, Michael A. ;

Kazi, Hala ;

Melo, Helen M. ;

McClean, Paula L. ;

Holscher, Christian ;

Arnold, Steven E. ;

Talbot, Konrad ;

Klein, William L. ;

Munoz, Douglas P. ;

Ferreira, Sergio T. ;

De Felice, Fernanda G. .

JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (04) :1339-1353

[5] Prediabetes and Cardiovascular Disease Pathophysiology and Interventions for Prevention and Risk Reduction [J].

Brannick, Ben ;

Dagogo-Jack, Sam .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) :33-+

[6] Diabetes mellitus - A hypercoagulable state [J].

Carr, ME .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2001, 15 (01) :44-54

[7] GLP1 agonists beyond glycemic control-redefining their role [J].

Chowdhury, Subhankar ;

Goswami, Soumik .

INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2020, 40 (04) :461-463

[8] Aortic Stiffness, Cerebrovascular Dysfunction, and Memory [J].

Cooper, Leroy L. ;

Mitchell, Gary F. .

PULSE, 2016, 4 (2-3) :69-77

[9] Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia A Randomized Clinical Trial [J].

Craft, Suzanne ;

Raman, Rema ;

Chow, Tiffany W. ;

Rafii, Michael S. ;

Sun, Chung-Kai ;

Rissman, Robert A. ;

Donohue, Michael C. ;

Brewer, James B. ;

Jenkins, Cecily ;

Harless, Kelly ;

Gessert, Devon ;

Aisen, Paul S. .

JAMA NEUROLOGY, 2020, 77 (09) :1099-1109

[10] Cardiovascular safety and benefits of GLP-1 receptor agonists [J].

Dalsgaard, Niels B. ;

Bronden, Andreas ;

Vilsboll, Tina ;

Knop, Filip K. .

EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) :351-363

← 1 2 3 4 5 6 7 →